**Indirect treatment comparison (ITC) of the efficacy of vutrisiran and tafamidis for hereditary transthyretin-mediated amyloidosis with polyneuropathy**

**Table of abbreviations**

|  |  |
| --- | --- |
| AE | Adverse event |
| ATTRv | Hereditary transthyretin-mediated |
| BMI | Body Mass Index |
| CI | Confidence Interval |
| COVID-19 | coronavirus 2019 |
| FAP | Familial Amyloid Polyneuropathy |
| hATTR | Hereditary transthyretin-mediated |
| HRQOL | Health-related quality of life |
| I/E | Inclusion and exclusion |
| ITC | Indirect treatment comparison |
| ITT | Intention-to-treat |
| IV | Intravenous |
| LOCF | last-observation-carried-forward |
| LSMD | Least squares mean difference |
| MAIC | matching-adjusted indirect comparisons |
| mBMI | Modified Body Mass Index |
| mITT | Modified intention-to-treat |
| MMRM | Mixed model repeated measures |
| mNIS+7 | Modified Neuropathy Impairment Score +7 |
| NIS | Neuropathy Impairment Score |
| NIS-LL | Neuropathy Impairment Score - Lower Limbs |
| NIS+7 | Neuropathy Impairment Score +7 |
| Norfolk QOL-DN | Norfolk Quality of Life – Diabetic Neuropathy questionnaire |
| OR | Odds ratio |
| PND | Polyneuropathy Disability |
| Q3M | Every three months |
| Q3W | Every three weeks |
| RCT | Randomized controlled trial |
| RD | Risk difference |
| RNAi | Ribonucleic acid interference |
| RR | Risk ratio |
| SC | subcutaneous |
| SD | Standard deviation |
| TTR | Transthyretin |
| V30M | Valine to methionine variant at amino acid 30 |